PARTNER Trial Transcatheter Valve Results Will be Presented at TCT

 

September 15, 2010

September 15, 2010 – Results from the PARTNER Trial Cohort B will be presented at 11 a.m. on Thursday, Sept. 23, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium in Washington, D.C.

The PARTNER Trial is the world's first randomized clinical trial of a transcatheter heart valve and is studying the Edwards Lifesciences Corp. Sapien heart valve. Cohort B compares the Sapien to treatment with medical management in inoperable patients. The transcatheter valve is an investigational device in the United States and not yet available commercially in this country.

PARTNER is among the most important late-breaking trials being presented at TCT this year. TCT organizers said it has the potential to change how structural heart disease is treated in the future. The data presented will also factor into U.S. Food and Drug Administration (FDA) consideration of the Sapien device.

For more information: www.edwards.com